SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Cortexyme, Inc., a privately held, clinical stage biopharmaceutical
company pioneering a novel disease-modifying therapeutic approach to
treat a key underlying cause of Alzheimer’s disease (AD) and other
degenerative diseases, today announced the election of veteran biopharma
finance executive Christopher J. Senner to the company’s Board of
Directors.
“Chris Senner’s deep financial expertise, gained at some of our
industry’s most notable companies, makes him an important addition to
the Cortexyme Board of Directors,” said Casey Lynch, Cortexyme’s
co-founder and chief executive officer. “Cortexyme will benefit greatly
from his experience spanning both clinical and commercial stage
organizations as we move forward into late stage development of our lead
drug candidate, COR388.”
Mr. Senner has nearly three decades of finance experience at
industry-leading biotechnology and pharmaceutical companies. He
currently serves as Executive Vice President and Chief Financial Officer
of Exelixis, Inc. (EXEL), a commercially successful, oncology-focused
biotech advancing medicines for difficult-to-treat cancers. At Exelixis,
Mr. Senner leads a team responsible for providing the financial
infrastructure for the company’s growing commercial oncology franchise,
broad clinical development operations, and reinitiated drug discovery
activities. Before joining Exelixis, Mr. Senner served for five years as
Vice President, Corporate Finance at Gilead Sciences. Prior to Gilead,
he spent eighteen years at Wyeth, including as CFO of its U.S.
pharmaceuticals business and BioPharma Business Unit. Mr. Senner holds a
B.S. in Finance from Bentley College.
“In the span of just a few years, Cortexyme has efficiently progressed a
promising first-in-class approach to treating an underlying cause of
Alzheimer’s into a potentially pivotal study,” said Mr. Senner. “I’m
looking forward to sharing my financial expertise with the Cortexyme
team as the company executes on its plans to transform the treatment of
degenerative disease.”
About Cortexyme
Cortexyme is a privately held, clinical-stage pharmaceutical company
pioneering a novel disease-modifying therapeutic approach to treat a key
underlying cause of Alzheimer’s disease and other degenerative diseases.
Cortexyme is targeting a specific, infectious pathogen found in the
brain of Alzheimer’s patients and tied to neurodegeneration and
neuroinflammation in animal models. The company’s lead compound, COR388,
is beginning the Phase 2/3 GAIN trial in Alzheimer’s disease in the
second quarter of 2019; more information can be found on ClinicalTrials.gov.
For more information on Cortexyme, visit www.cortexyme.com.
Contacts
Hal Mackins
For Cortexyme, Inc.
hal@torchcomllc.com
(415)
994-0040